Patients looking to save on antipsychotics have a new option. The patent protecting Johnson & Johnson’s blockbuster Risperdal expired yesterday, and today the FDA said it granted approval to Teva Pharmaceuticals to market the first generic version.
|
Tuesday, July 1, 2008
Generic Risperdal Hits the Market
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment